About Biora Therapeutics
Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic,
needle-free delivery of biotherapeutics, the company is developing therapies to improve patients lives.
Biora is focused on development of two
therapeutics platforms: the NaviCap targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site
of disease in the gastrointestinal tract, and the BioJet systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through
needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or
Twitter.
Safe Harbor Statement or Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including
statements concerning the progress and future expectations and goals of our research and development and clinical efforts including phase 1 trial readiness, phase 1 trial execution timeline, phase 1 trial commencement, and working through the final
FDA and trial site requirements prior to enrolling the first subject, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will,
objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential,
plan, target, or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release.
These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and
other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval,
clearance, or acceptance of our clinical trials or products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results,
our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve
our business objectives, and those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form
10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.